利加隆联合恩替卡韦治疗慢性乙型肝炎疗效观察  

The Efficacy of Lijialong Joint Entecavir in the Treatment of Chronic Hepatitis B

作　　者：李传生[1] 

机构地区：[1]淮安市盱眙县人民医院,江苏淮安211700

出　　处：《深圳中西医结合杂志》2015年第22期73-74,共2页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:评价利加隆联合恩替卡韦治疗慢性乙型肝炎临床疗效及乙型肝炎病毒脱氧核糖核酸(HBV-DNA)转阴率的近期疗效。方法:采用随机、双盲、平行对照的方法,122例伴有谷丙转氨酶(ALT)升高的慢乙肝患者分为两组:治疗组62例;给予利加隆联合恩替卡韦治疗,对照组60例,给予恩替卡韦治疗,其他治疗两组相同,均未使用免疫调节药物及糖皮质激素,检测用药前后两组患者谷丙转氨酶、总胆红素、白蛋白和血清肝纤维化指标及HBV-DNA的变化。结果:恩替卡韦联合利加隆的治疗组血清肝纤维化指标(透明质酸、层粘蛋白、IV型胶原)和肝功能指标(谷氨转氨酶、总胆红素)下降明显,白蛋白上升明显,分别与治疗前和对照组比较,差异具有统计学意义(P<0.05)。两组患者在治疗3、6个月时HBV-DNA转阴率比较,差异无统计学意义(P>0.05)。结论:利加隆联合恩替卡韦在慢性乙型肝炎患者肝功能恢复正常,血清肝纤维化指标下降等方面的作用优于单独使用恩替卡韦,但两种方法对慢性乙型肝炎病毒下降水平,差异无统计学意义(P>0.05)。Objective To evaluate the effect of Lijialong joint entecavir on chronic hepatitis B and clinical efficacy of hepatitis B virus HBV-DNA negative rate. Methods A randomized, double-blind, parallel-group approach, 122 cases with alanine aminotransferase（ALT） elevation chronic hepatitis B patients were divided into two groups： the treatment group of 62 patients received Lijialong entecavir treatment; control group, 60 cases given entecavir treatment, the two groups were measured before and after treatment alanine aminotransferase, total bilirubin, albumin, and serum liver fibrosis and changes in indicators of HBVDNA. Results Entecavir therapy combined with Lijialong serum fibrosis markers（hyaluronic acid, laminin, 1V collagen） and liver function parameters（glutamic transaminase, total bilirubin） decreased significantly, albumin increased significantly, respectively before treatment and control group there was significant difference, P〈0.05. Two groups of patients at 3 and 6 months of treatment HBV-DNA negative rate was not statistically significant（P〉0.05）. Conclusion Lijialong joint entecavir in liver function in patients with chronic hepatitis B returned to normal, the role of serum fibrosis markers and other aspects of superior decline entecavir alone, but the two methods of chronic hepatitis B virus was no significant difference in the level of decline.

关 键 词：慢性乙型肝炎 恩替卡韦 利加隆 肝纤维化 

分 类 号：R512.62[医药卫生—内科学]